ABVX ABIVAX Société Anonyme
87.01USD-1.37%Mkt Cap: 7.59B $P/E: —1d ago
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.…
Industry Peers
BiotechnologyKey Statistics
Company
Market Cap7.59B USD
Enterprise Value6.64B USD
Revenue (TTM)4.67M USD
Gross Profit4.67M USD
Net Income (TTM)-336.10M USD
Revenue/Share0.06 USD
Last Price87.01 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees98
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-22.73
PEG—
EV/EBITDA-22.78
EV/Revenue1422.51
P/S1649.33
P/B17.08
EPS (TTM)-6.08
EPS (Forward)-3.88
52W Range
69.8122% of range148.83
52W High148.83 USD
52W Low69.81 USD
Profitability
Gross Margin100.00%
Oper. Margin-8617.93%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-73.84%
ROA-57.52%
Growth
Revenue Growth-6.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-161.13M USD
CapEx (TTM)142.00K USD
FCF Margin-2697.05%
FCF Yield-1.66%
Net Debt-401.17M USD
Net Debt/EBITDA1.38
Balance Sheet
Debt/Equity0.00
Current Ratio5.96
Quick Ratio5.79
Book Value/Sh5.17 USD
Cash/Share5.04 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)164.00 USD
Upside (mean)+88.5%
Target Range142.00 USD – 181.00 USD
142.00+88.5% to mean181.00
# Analysts12
Ownership
Shares Out.87.27M
Float69.03M
Insiders0.00%
Institutions71.73%
Short Interest
Short Ratio6.8d
Short % Float7.95%
Short % Out.7.86%
Shares Short6.86M
Short (prev mo.)6.00M
Technical
SMA 50113.54 (-23.4%)
SMA 200117.74 (-26.1%)
Beta-0.23
S&P 52W Chg16.45%
Avg Vol (30d)1.23M
Avg Vol (10d)1.52M
Technical Indicators
RSI (14)27.4
MACD-7.1956
MACD Signal-6.4549
MACD Hist.-0.7407
BB Upper122.84 USD
BB Middle101.47 USD
BB Lower80.10 USD
BB Width42.13%
ATR (14)4.608 USD
Vol Ratio (20d)0.96x